Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology characterized by the development of subpleural foci of myofibroblasts that contribute to the exuberant fibrosis noted in the pulmonary parenchyma. Pleural mesothelial cells (PMC) are metabolically dynamic cells that cover the lung and chest wall as a monolayer and are in intimate proximity to the underlying lung parenchyma. The precise role of PMC in the pathogenesis of pulmonary parenchymal fibrosis remains to be identified. TGF-β1, a cytokine known for its capacity to induce proliferative and transformative changes in lung cells is found in significantly higher quantities in the lungs of patients with IPF. High levels of TGF-β1 in the subpleural milieu may play a key role in the transition of normal PMC to myofibroblasts. Here we demonstrate that PMC activated by TGF-β1 undergo epithelial mesenchymal transition (EMT), respond with haptotactic migration to a gradient of TGF-β1 and that the transition of PMC to myofibroblasts is dependent on smad-2 signaling. The EMT of PMC was marked by upregulation of alpha-smooth muscle actin (α-SMA), fibroblast specific protein-1 (FSP-1) and collagen type-I expression. The cytokeratin-8 (Ck-8), and E-cadherin expression decreased whereas vimentin remained unchanged over time in transforming PMC. Knockdown of smad-2 gene by silencing siRNA significantly suppressed the transition of PMC to myofibroblasts and significantly inhibited the PMC haptotaxis. We conclude that PMC undergo EMT when exposed to TGF-β1, involving smad-2 signaling and PMC may be the possible source of myofibroblasts in IPF.
INTRODUCTION
Pulmonary fibrosis is a progressive and irreversible lung disease characterized by cellular and structural changes in the lung parenchyma and the formation of myofibroblasts particularly in subpleural foci. Virtually all these changes are attributed to increased deposition of extracellular matrix components including collagen and increased number of myofibroblasts expressing alpha-smooth muscle actin (α-SMA) (19, 28, 29) . Neither the origin of these cells nor the molecular mechanisms involved in the formation of myofibroblasts are clearly understood. The myofibroblast like cells that express α-SMA accumulate in the fibroblast foci of lung parenchyma are thought to be derived from a variety of sources. It was postulated that, myofibroblasts were derived from the circulating progenitor cells (1) , or from proliferative expansion of the resident mesenchymal cells (1, 19) . Currently it is believed that the fibroblasts are derived from tissues locally following the process of EMT (16). However, the possibility that PMC have the capability of transitioning into a mesenchymal or smooth muscle-like phenotype has not been postulated. We hypothesize that because of its intimate proximity to the lung parenchyma, the pleura can respond to inflammatory cytokines in the lung parenchyma, mesothelial cells can transform and invaginate into the lung in response to TGF-β1 and may play a key role in pulmonary parenchymal diseases including IPF (2, 32).
The pleural mesothelium is a metabolically active monolayer of cells covering the chest wall and lungs.
During parenchymal inflammation the PMC are exposed to a microenvironment with high levels of cytokines, chemokines and growth factors including 31, 41) . TGF-β1 is considered to be a master switch for the induction of fibrosis by a process of EMT in various organs including the lung (12, 44, 45, 47) . During stress/injury PMC attain plasticity, lose their polarity and mesothelial markers. The cellular transition of PMC leads to cytoskeleton reorganization acquiring spindle-shape morphology and expression of mesenchymal markers. FSP-1 is constitutively expressed in newly formed fibroblasts called myofibroblasts and considered a specific marker for EMT. Myofibroblasts are prominent components of fibrosis in many tissues including the pleura (11, 23, 40) . Transformed PMC express FSP-1 and α-SMA a myofibroblast protein suggesting the conversion of PMC to myofibroblast in the presence of TGF-β1. The transformed PMC lose the expression of adherens junctional protein Ecadherin, and cytokeratin. Moreover, activated PMC express fibroblast specific protein 1 (FSP-1).
TGF-β1 mediates EMT by inducing Smad signaling (6, 18) . Smads are the group of intracellular proteins that are critical for transmitting the TGF-β1 signals from the cell surface to the nucleus to promote transcription of target genes (36, 42) . The role of smad-3 in the development of dermal fibrosis, sub-capsular cataract, and pulmonary fibrosis has been reported (4, 34, 37). A transient overexpression of TGF-β1 using adenovirus resulted in severe fibrosis in rat lungs (39). However, the potential role of smad-2 in the development of fibrosis is unclear. In the present study we demonstrate in vitro that PMC undergo a transition from epithelial phenotype to mesenchymal phenotype in the presence of profibrotic growth factor TGF-β1. The TGF-β1 induced PMC phenotypic transition to myofibroblasts is dependent on smad-2 signaling, thus suggesting the possibility that PMC may be the source of myofibroblast in IPF. .
EXPERIMENTAL PROCEDURES
Small interfering-RNA (siRNA) treatment-The PMC were grown to a 70% confluence on culture dishes and the transient transfection was performed with specific stealth small interference RNA (siRNA) against smad-2, or control siRNA for over night using Lipfectamine-2000 (Invitrogen; Carlsbad, CA) , according the manufacturer's instructions.
The total of three siRNA sequences for smad-2 and control-siRNA were designed and Immunofluorescence staining-The expression of EMT markers in PMC was analyzed by immuno-fluorescence microscopy (Zeiss LSM 510 (Axiovert 100M), Zeiss, Thornwood, NY)
as reported earlier (25). In brief, the cells were cultured to confluence on collagen coated glass cover slips and fixed in 4% paraformaldehyde (with 50 mM phosphate buffer) in 50%
Tris wash buffer (TWB). The glass cover slips were rinsed three times and permeabilized with 1.2% Triton X-100 for 5 minutes, rinsed three times, incubated with 1% BSA in 100% TWB for 1 h, then stained for the expression markers using primary antibodies mouse anti- TGF-β1 treatment induces smad-2 and smad-4 phosphorylation in PMC undergoing phenotypic transformation. We examined the expression of smad-2, and smad-4 in PMC treated with TGF-β1 and resting PMC. The expression of smad-2 was evaluated at 96 hours in TGF-β1 treated and resting PMC ( Figure-2 ). High expression of smad-2 and samd-4 was noted up to 2 hours, and smad-2 expression was noted even at 24 hour ( Figure 6 ). However the expression of smad-4 was significantly down regulated after 2 hour of TGF-β1 treatment. Resting PMC showed minimal expression of smad-2 and smad-4. Phospho-smad-2 levels were increased significantly after TGF-β1 treatment. Smad-4 phosphorylation was minimal in TGF-β1 treated PMC when compared to control. These results suggest that smad-2 signaling pathway was clearly activated in PMC treated with TGF-β1 and not in resting cell. These results also indicate that TGF-β1 induced EMT changes were mediated through smad-2 signaling in PMC.
Silencing smad-2 signaling suppresses the TGF-β1 induced smad-2 expression in

PMC.
To determine the significance of smad-2 in the process of EMT we first evaluated the transfection efficiency and knock down of smad-2 gene. The siRNA-smad2 #1 was used for the silencing interference siRNA experiments based on the transfection efficiency and knockdown of smad-2 gene compared to other two siRNA sequences. About 85% Knockdown of smad2 gene was noted in the smad-2 #1 siRNA treatment compared to control siRNA ( Figure 7A ) in TGF-β1 treated PMC. Panel B. The blot was reprobed for smad-4 expression to evaluate the specificity of siRNA-smad2. Transfection of PMC with siRNA-smad2 did not effect the smad-4 expression which indicates that the siRNA designed is specific for silencing smad-2 expression. These results confirm that the siRNA is specific for silencing smad-2 signaling in PMC.
Silencing smad-2 signaling blocks TGF-β1 induced mesenchymal transformation in PMC. In order to confirm whether smad-2 is involved in TGF-β1 mediated EMT in PMC, siRNA were used to knock down smad-2 gene in PMC. We first confirmed the effect of siRNA-smad-2 on PMC treated with TGF-β1 by immuno-fluorescence staining. As shown in Figure-8 panel A, the expression of E-cadherin was significantly restored after the knockdown of smad-2 in TGF-β1 treated PMC when compared to their counterparts, control siRNA and PMC alone. Also α-SMA staining was less intense in PMC after the knockdown of smad-2 in the presence of TGF-β1. Notably, the expression of α-SMA assumed less fibrillar pattern and exhibited a diffuse granular cytoplasmic distribution ( Figure-8 B) . Further more cellular morphology of TGF-β1 treated PMC reverted from a spindle shape to a more cuboidal/cobble stone shape, after the knock down of smad-2.
This effect was not observed in the control siRNA treated PMC in the presence of TGF-β1.
The phase-contrast microscopy of the cultures revealed that knockdown of smad-2 in TGF-β1 treated PMC significantly reversed the spindle-shaped morphology to a cobble-stone appearance; however the spindle shaped morphology was preserved in the control siRNA transfected PMC as shown in Panel C. We also evaluated the expression of E-cadherin and α-SMA in total cell lysates by Western blot analysis, after silencing smad-2 by using siRNA-samd-2 or control-siRNA in PMC treated with TGF-β1. We noted a remarkably reduced expression of α-SMA, and most importantly a significant restoration of junctional protein E-cadherin suggesting the role of smad-2 signaling in EMT of PMC (Figure-8 D) .
Panel E, PMC were transfected with silencing siRNA of smad-2 and the expression of FSP-1 was evaluated. A significant knockdown of FSP-1 gene expression was noticed in PMC treated with TGF-β1 compared to control siRNA (Figure-7B ). This suggests that the mesenchymal changes induced by TGF-β1 are regulated by smad-2 signaling in PMC.
Silencing smad-2 signaling blocks PMC haptotaxis in response to TGF-β1.
Haptotactic migration of PMC was evaluated with and without TGF-β1. PMC showed a significantly increased haptotactic activity with TGF-β1 compared to BSA (bovine serum albumin) control. Optimum haptotaxis of PMC was noted at a dose of 5ng TGF-β1 ( Figure   9 Panel A). PMC haptotaxis was also evaluated against TGF-β1 after the activation of PMC with recombinant TGFβ-1 for 24h, 48h, 72h and 96h and compared with serum free medium (SFM) cultured PMC. A remarkable increase in the haptotaxis of PMC was noted up to 72h however, the haptotactic migration of PMC was plateaued there after ( Figure 9 Panel B). PMC transfected with siRNA smad-2 showed significantly suppressed haptotaxis with TGF-β1 when compared to control siRNA transfected PMC ( 
DISCUSSION
In this study we demonstrate that human PMC respond to TGF-β1 by transformation into myofibroblasts in vitro; indicating that these cells have the capacity to initiate, and modulate the expression of epithelial markers to mesenchymal markers to undergo EMT.
The pleural mesothelium is in intimate proximity to the lung, and is responsive to inflammatory events occurring in the lung parenchyma (2, 32). Because PMC can transform into myofibroblast like phenotype and migrate via haptotaxis in response to TGF- Recently, it has been recognized that besides inflammation mechanical stress could also contribute in the cascade of events that results in altering lung cell phenotype (43).
The role of mechanical stress in the regulation of cardiovasculatrue and fibroblast function have been reported (22, 33) . Although very little is known about the mechanism, it is of interest that mechanical stress promotes matrix production. However, the signaling pathways need to be elucidated. It may be possible that mechanical stress sub-pleurally could in part, trigger EMT.
IPF is a progressive disease of fibrosis characterized by fibroblastic foci in the lung parenchyma. Cool et. al., described the parenchymal fibrosis found in patients with IPF as an interconnected wave of fibrosis that progressed from the pleura into the lung parenchyma (9). The authors suggest that the fibrosis is continuous with the pleura and then advances as a connected three dimensional wave of fibrosis into the lung parenchyma and hint that this finding should alter our underlying assumptions regarding the initiation and progression of IPF (9). The growth factor TGF-β1 contributes to the development of fibroblastic foci in the sub-pleural region, and several studies have focused on the role of transforming growth factor-β1 as the key promoter of fibrosis in the lung of patients with IPF (14, 20, 21, 35, 44) . However, the precise mechanisms responsible for the formation of fibroblastic foci are unknown and the origin of myofibroblasts a critical element in the process of fibrosis is not clearly understood. It is recognized that injury to pleural mesothelium precedes the formation of pleural fibroblasts and PMC may therefore contribute to their formation, through the production of key fibrogenic mediators including TGF-β1 (11, 15). Our data demonstrates that PMC undergo transition from epithelial to mesenchymal phenotype upon activation with TGF-β1, with the induction of transcription factor smad-2 and dramatic down-regulation of ck-8 and junctional protein E-cadherin expression.
Recent studies by Quintana et. al. identified the pleura as a major site of inflammation in rats challenged with inhaled endotoxin or ovalbumin in ova-albumin sensitized animals (32). Using MRI they demonstrated a significant MRI signal from the pleura that correlated with histological analysis of lung pleural tissue in animals where the primary site of injury was the lung parenchyma, indicating that pleural mesenchymal cells are actively responsive to insults in the lung parenchyma (32). The findings suggest that the pleura is metabolically active and is highly sensitive to the underlying cytokine milieu, and responds rapidly suggesting that a minor injury in the lung parenchyma would be enough to initiate inflammation in the pleura and perhaps lead to the subsequent series of signaling events resulting in phenotypic transformation.
Haptotaxis is defined as the movement of cells in response to a dose dependent gradient of substratum bound cytokine. PMC were found to respond with haptotaxis to a gradient of cytokine TGF-β1. A total loss of cobble-stone morphology was noticed in primary PMC.
PMC progressively lost the expression of E-cadherin, and Ck-8 when activated with TGF- 
